Zobrazeno 1 - 10
of 233
pro vyhledávání: '"H. Ludlam"'
Autor:
Eliza B. Geer, Jill Sisco, Daphne T. Adelman, William H. Ludlam, Asi Haviv, Shuqian Liu, Susan D. Mathias, Dana Gelbaum, Lizheng Shi
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Acromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, an
Externí odkaz:
https://doaj.org/article/62aa9e604c8d4aadb861a8c07a576255
Autor:
Maria Fleseriu, Mark Molitch, Alexander Dreval, Nienke R. Biermasz, Murray B. Gordon, Ross D. Crosby, William H. Ludlam, Asi Haviv, Yossi Gilgun-Sherki, Susan D. Mathias
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Medical treatment for acromegaly commonly involves receiving intramuscular or deep subcutaneous injections of somatostatin receptor ligands (SRLs) in most patients. In addition to side effects of treatment, acromegaly patients often still experience
Externí odkaz:
https://doaj.org/article/345eef4e06e5413793db0d9ad794e047
Autor:
George A H Ludlam, Decio F Alves de Lima, Xiaoran Li, Bethan Coulson, Emily Nesling, Riccardo Degl'Innocenti, Richard Dawson, Massimo Peruffo, Hungyen Lin
Publikováno v:
2022 47th International Conference on Infrared, Millimeter and Terahertz Waves (IRMMW-THz).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d3150ae7514f6b58f1cc07964c473c8
https://doi.org/10.1109/irmmw-thz50927.2022.9895912
https://doi.org/10.1109/irmmw-thz50927.2022.9895912
Publikováno v:
Case Reports in Endocrinology, Vol 2016 (2016)
Introduction. Frequent colonoscopy screenings are critical for early diagnosis of colon cancer in patients with acromegaly. Case Presentations. We performed a retrospective analysis of the incidental diagnoses of colon cancer from the ACCESS trial (C
Externí odkaz:
https://doaj.org/article/25180b8288044c87be73ebbfa5593ff7
Autor:
Laurence Kennedy, Andrea Giustina, Asi Haviv, Peter J Trainer, William H. Ludlam, Artak Labadzhyan, Gary Patou, Marek Bolanowski, Maria Fleseriu, Shlomo Melmed, Nienke R. Biermasz, Murray B. Gordon, Susan L. Samson, Lisa B. Nachtigall, Mark E. Molitch, Ehud Ur, Christian J. Strasburger
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism, 105(10), e3785-e3797. ENDOCRINE SOC
Journal of Clinical Endocrinology and Metabolism, 105(10), e3785-e3797. ENDOCRINE SOC
Purpose The phase 3 CHIASMA OPTIMAL trial (NCT03252353) evaluated efficacy and safety of oral octreotide capsules (OOCs) in patients with acromegaly who previously demonstrated biochemical control while receiving injectable somatostatin receptor liga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e527dc803131c2e4036a26329b20c7
https://doi.org/10.1210/clinem/dgaa526
https://doi.org/10.1210/clinem/dgaa526
Autor:
Shuqian Liu, Eliza B Geer, Susan D. Mathias, William H. Ludlam, Asi Haviv, Lizheng Shi, Jill Sisco, Daphne T. Adelman, Dana Gelbaum
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Endocrine Disorders
BMC Endocrine Disorders
Background Acromegaly patients managed on Somatostatin receptor ligands (SRLs), the most common first-line pharmacotherapy for acromegaly, may still experience acromegaly symptoms such as headache, sweating, fatigue, soft tissue swelling, and joint p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7f8704c94bd01f2fc958687be5b775
http://link.springer.com/article/10.1186/s12902-020-00595-4
http://link.springer.com/article/10.1186/s12902-020-00595-4
Autor:
William H. Ludlam, Maria Fleseriu, Leon Fogelfeld, Susan D. Mathias, Jill Sisco, Ross D. Crosby, Murray B. Gordon, Asi Haviv
Publikováno v:
Pituitary
Purpose The Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) is a new patient-reported outcome (PRO) measure for patients with acromegaly receiving injectable somatostatin analogs (SSAs) to assess clinical symptoms and adverse drug reaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d720b08dc8234fd6070c8e9e54ca11b7
http://europepmc.org/articles/PMC7316852
http://europepmc.org/articles/PMC7316852
Autor:
Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J Manning, Atanaska Elenkova, Mark E Molitch, William H Ludlam, Gary Patou, Asi Haviv, Nienke R Biermasz, Andrea Giustina, Christian J Strasburger, Laurence Kennedy, Shlomo Melmed
Publikováno v:
European journal of endocrinology, 187(6), 733-741. OXFORD UNIV PRESS
Objective The objective of this study is to report results from the open-label extension (OLE) of the OPTIMAL trial of oral octreotide capsules (OOC) in adults with acromegaly, evaluating the long-term durability of therapeutic response. Design The s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14aca7bf8112ac1ad3f4bdbdad4f8338
https://pubmed.ncbi.nlm.nih.gov/36173649
https://pubmed.ncbi.nlm.nih.gov/36173649
Autor:
Dana Gelbaum, Shuqian Liu, Daphne T. Adelman, William H. Ludlam, Asi Haviv, Jill Sisco, Susan D. Mathias, Lizheng Shi, Eliza B Geer
Publikováno v:
Pituitary
Background Acromegaly patients, even those with IGF-1 values within the normal range receiving somatostatin receptor ligands (SRLs), often suffer from significant symptoms. It is not known to what extent patients’ medical providers are aware of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2d2109cbf6fa19c7aede005fd008c29
https://doi.org/10.1007/s11102-019-01013-2
https://doi.org/10.1007/s11102-019-01013-2
Autor:
Mark E. Molitch, William H. Ludlam, Wenyu Huang, Nienke R. Biermasz, Akexander V Dreval, Elena Isaeva, Nina Leonova, Christian J. Strasburger, Pamela U. Freda, Murray B. Gordon, Gary Patou, Yossi Gilgun-Sherki, Djuro P Macut, Shlomo Melmed, Yulia Pokramovich, Asi Haviv, Irina Bondar, Gérald Raverot, Maria Fleseriu
Publikováno v:
Journal of the Endocrine Society
Background: Injectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the United States. Results from the placebo-controlled CHIASMA OPTIMAL and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c62516487d07aa94d1e3834b797c00a7
https://doi.org/10.1530/endoabs.73.pep3.2
https://doi.org/10.1530/endoabs.73.pep3.2